Literature DB >> 27249031

One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity.

Daniel L Hertz1, James M Rae2.   

Abstract

Entities:  

Keywords:  CYP2D6; clinical utility; clinical validity; endoxifen; estrogen receptor positive breast cancer; tamoxifen

Mesh：

Substances：

Year:  2016        PMID： 27249031     DOI： 10.2217/pgs-2016-0059

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  8 in total

1.  Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.

Authors:  Xiaoxia Wei; Hong Sun; Jie Zhuang; Xiuhua Weng; Bin Zheng; Qiwang Lin; Guifeng Zhang; Jiaqin Cai
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

2.  CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

Authors:  D L Hertz; K M Kidwell; S G Hilsenbeck; S Oesterreich; C K Osborne; S Philips; C Chenault; R J Hartmaier; T C Skaar; M J Sikora; J M Rae
Journal:  Breast Cancer Res Treat       Date:  2017-07-20       Impact factor: 4.872

3.  Limited influence of germline genetic variation on all-cause mortality in women with early onset breast cancer: evidence from gene-based tests, single-marker regression, and whole-genome prediction.

Authors:  Molly Scannell Bryan; Maria Argos; Irene L Andrulis; John L Hopper; Jenny Chang-Claude; Kathleen Malone; Esther M John; Marilie D Gammon; Mary Daly; Mary Beth Terry; Saundra S Buys; Dezheng Huo; Olofunmilayo Olopade; Jeanine M Genkinger; Farzana Jasmine; Muhammad G Kibriya; Lin Chen; Habibul Ahsan
Journal:  Breast Cancer Res Treat       Date:  2017-05-13       Impact factor: 4.872

4.  Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.

Authors:  Werner Schroth; Stefan Winter; Thomas Mürdter; Elke Schaeffeler; Diana Eccles; Bryony Eccles; Balram Chowbay; Chiea C Khor; Arafat Tfayli; Nathalie K Zgheib; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch
Journal:  Front Pharmacol       Date:  2017-08-24       Impact factor: 5.810

5.  CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer.

Authors:  Wei He; Felix Grassmann; Mikael Eriksson; Erik Eliasson; Sara Margolin; Linda Thorén; Per Hall; Kamila Czene
Journal:  J Clin Oncol       Date:  2019-12-04       Impact factor: 44.544

6.  Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.

Authors:  Thomas Helland; Bjørn Naume; Steinar Hustad; Ersilia Bifulco; Jan Terje Kvaløy; Anna Barbro Saetersdal; Marit Synnestvedt; Tone Hoel Lende; Bjørnar Gilje; Ingvil Mjaaland; Kjetil Weyde; Egil Støre Blix; Gro Wiedswang; Elin Borgen; Daniel Louis Hertz; Emiel Adrianus Maria Janssen; Gunnar Mellgren; Håvard Søiland
Journal:  Mol Oncol       Date:  2020-12-14       Impact factor: 6.603

7.  (Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study.

Authors:  Thais Almeida; Werner Schroth; Jeanine Nardin; Thomas E Mürdter; Stefan Winter; Solane Picolotto; Reiner Hoppe; Jenifer Kogin; Elisa Gaio; Angela Dasenbrock; Raquel Cristina Skrsypcsak; Lucia de Noronha; Matthias Schwab; Hiltrud Brauch; José Claudio Casali-da-Rocha
Journal:  J Pers Med       Date:  2022-03-22

8.  Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos.

Authors:  Jorge-Aarón Rangel-Méndez; Rodrigo Rubi-Castellanos; Juan-Francisco Sánchez-Cruz; Rosa Esther Moo-Puc
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.